概述
-
货号
DVV03801
-
描述
Diridavumab, the alternative names CR6261, is a human monoclonal antibody direct against influenza A hemagglutinin. The CR6261 antibody was first discovered by the Scripps Institute and Crucell, a dutch biopharmaceutical company, and later developed by Janssen Pharmaceutical Companies of Johnson & Johnson under the trade name diridavumab. Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of Diridavumab in Japanese Healthy Participants).
-
表达系统
Mammalian Cells -
种属反应性
Influenza A virus -
宿主
Human -
同种型
IgG1, lambda -
克隆类型
Monoclonal -
靶标
HA/Hemagglutinin -
浓度
1.41 mg/ml -
内毒素水平
Please contact with the lab for this information. -
纯度
>95% as determined by SDS-PAGE. -
纯化方式
Protein A/G purified from cell culture supernatant. -
Accession号
-
克隆号
Diridavumab
-
应用
Research Grade Biosimilar -
状态
Liquid -
保存溶液
0.01M PBS, pH 7.4. -
稳定性和存储
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. -
别名
CR-6261, CR6261, CAS: 1393659-46-5
图片
参考文献
评价
